BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody devel… Read more
Market Cap & Net Worth: BIOCYTOGEN PHARMA. H YC1 (I54)
BIOCYTOGEN PHARMA. H YC1 (F:I54) has a market capitalization of $651.13 Million (€634.34 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #7986 globally and #846 in its home market, demonstrating a -11.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCYTOGEN PHARMA. H YC1's stock price €5.90 by its total outstanding shares 107515313 (107.52 Million).
BIOCYTOGEN PHARMA. H YC1 Market Cap History: 2022 to 2026
BIOCYTOGEN PHARMA. H YC1's market capitalization history from 2022 to 2026. Data shows growth from $326.67 Million to $651.13 Million (20.52% CAGR).
BIOCYTOGEN PHARMA. H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCYTOGEN PHARMA. H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of I54 by Market Capitalization
Companies near BIOCYTOGEN PHARMA. H YC1 in the global market cap rankings as of March 19, 2026.
Key companies related to BIOCYTOGEN PHARMA. H YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BIOCYTOGEN PHARMA. H YC1 Historical Marketcap From 2022 to 2026
Between 2022 and today, BIOCYTOGEN PHARMA. H YC1's market cap moved from $326.67 Million to $ 651.13 Million, with a yearly change of 20.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €651.13 Million | +57.33% |
| 2025 | €413.86 Million | +316.67% |
| 2024 | €99.33 Million | -47.67% |
| 2023 | €189.82 Million | -41.89% |
| 2022 | €326.67 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BIOCYTOGEN PHARMA. H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $651.13 Million USD |
| MoneyControl | $651.13 Million USD |
| MarketWatch | $651.13 Million USD |
| marketcap.company | $651.13 Million USD |
| Reuters | $651.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.